Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive lo... von Johnston, Stephen RD, Prof, Kilburn, Lucy S, MSc, Ellis, Paul, Prof, Dodwell, David, Prof, Cameron, David, Prof, Hayward, Larry, MD, Im, Young-Hyuck, MD, Braybrooke, Jeremy P, MD, Brunt, A Murray, MD, Cheung, Kwok-Leung, MD, Jyothirmayi, Rema, MD, Robinson, Anne, MD, Wardley, Andrew M, MD, Wheatley, Duncan, MD, Howell, Anthony, Prof, Coombes, Gill, RGN, Sergenson, Nicole, BSc, Sin, Hui-Jung, BSc, Folkerd, Elizabeth, PhD, Dowsett, Mitch, Prof, Bliss, Judith M, Prof

Volltext

Combinations of Endocrine and Biological Agents: Present Status of Therapeutic and Presurgical Investigations von Johnston, Stephen Rd

Volltext

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breas... von Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F, Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Chapman, Sonya C, Price, Gregory L, Yang, Zhengyu, Gainford, M Corona, André, Fabrice

Volltext

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer von Leary, Alexandra F, Sirohi, Bhawna, Johnston, Stephen R D

Volltext

Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer von Lee, Karla A, Shepherd, Scott Tc, Johnston, Stephen Rd

Volltext

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer von Li, Weimin, O'Shaughnessy, Joyce, Hayes, Daniel, Campone, Mario, Bondarenko, Igor, Zbarskaya, Irina, Brain, Etienne, Stenina, Marina, Ivanova, Olga, Graas, Marie-Pascale, Neven, Patrick, Ricci, Deborah, Griffin, Thomas, Kheoh, Thian, Yu, Margaret, Gormley, Michael, Martin, Jason, Schaffer, Michael, Zelinsky, Kathy, De Porre, Peter, Johnston, Stephen R D

Volltext

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard- of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced brea... von Tolaney, Sara M., Wardley, Andrew M., Zambelli, Stefania, Hilton, John F., Troso-Sandoval, Tiffany A., Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen Rd, Chan, Arlene, Goel, Shom, Catron, Kristen, Chapman, Sonya C., Price, Gregory L., Yang, Zhengyu, Gainford, M. Corona, Andre, Fabrice

Volltext

Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapam... von JOHNSTON, Stephen R. D

Volltext

BOLERO-2 - will this change practice in advanced breast cancer? von Johnston, Stephen Rd

Volltext

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer von Roylance, Rebecca, Endesfelder, David, Jamal-Hanjani, Mariam, Burrell, Rebecca A., Gorman, Patricia, Sander, Jil, Murphy, Niamh, Birkbak, Nicolai Juul, Hanby, Andrew M., Speirs, Valerie, Johnston, Stephen R. D., Kschischo, Maik, Swanton, Charles

Volltext

Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemothera... von Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F., Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Yang, Zhengyu, Gianford, M. Corona, Price, Gregory L, André, Fabrice

Volltext

Introduction: are current drug development programmes realising the full potential of new agents? von Johnston, Stephen R D, Bhatanager, Ajay

Volltext

New targets for therapy in breast cancer: farnesyltransferase inhibitors von Head, Julia, Johnston, Stephen R D

Volltext

Are current drug development programmes realising the full potential of new agents? The scenario von Johnston, Stephen R D

Volltext

Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? von Johnston, Stephen R D

Volltext

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8 von Johnston, Stephen R D

Volltext

Integration of endocrine therapy with targeted agents von Johnston, Stephen R D

Volltext

Farnesyl transferase inhibitors: a novel targeted therapy for cancer von Johnston, Stephen RD

Volltext

Acquired tamoxifen resistance in human breast cancer–potential mechanisms and clinical implications von Johnston, Stephen RD

Volltext

Ovarian Cancer: Review of the National Institute for Clinical Excellence (NICE) Guidance Recommendations von Johnston, Stephen RD

Volltext